Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Aktis Oncology, Inc.NASDAQ: AKTS
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI of -$241K in Q1 FY2026
Q1 FY2026 Accumulated OCI was -$241K.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 42K USD
- Year-over-year change
- -66.1%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42K | -66.1% |
| FY2024 | 2024-12-31 | 124K | +51.2% |
| FY2023 | 2023-12-31 | 82K | — |
| FY2022 | 2022-12-31 | 0 | — |
Accumulated OCI vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 Accumulated OCI of -$241K is the 3rd highest of the 6 companies compared; the peer median is -$467K.
- Accumulated OCI amounts to 0.0% of total assets for AKTS, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$27K | -2600.0% | — | 0.0% | |
| Mar 2026 | -$207K | -297.1% | — | 0.2% | |
| Mar 2026 | -$241K | — | — | 0.0% | |
| Sep 2026 | -$467K | — | — | 0.1% | |
| Mar 2026 | -$5.28M | -261.3% | — | 0.8% | |
| Mar 2026 | -$35.37M | -6.9% | — | 3.3% | |
| Peer median (excluding AKTS) | -$467K | -279.2% | — | 0.2% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.